Test Directory

Herediatry Cancer Multigene Panel Test (174 Genes)

Herediatry Cancer Multigene Panel Test (81 Genes)

Hereditary Breast-Ovarian/Gynaecologic Cancer Panel (31 Genes)

Hereditary Colon & gastric cancer, with/without polyposis (35 Genes)

Hereditary Hematopoietic Malignancy/Immunodeficiency Predisposition panel (157 Genes)

Hereditary Leukaemia and Breast Cancer Panel (37 Genes)

Hereditary Lymphoid Malignancy/Immunodeficiency Predisposition Panel (73 Genes)

Hereditary Melanoma Panel (16 Genes)

Hereditary Multiple Exostoses Panel

Hereditary Myeloid/Myelodysplastic Syndrome/ Inherited predisposition to acute myeloid leukaemia (112 Genes)

Hereditary Pancreatits-single mutation (SPINK1 - N34S)

Hereditary Pheochromocytoma and Paraganglioma Panel (10 Genes)

Hereditary Prostate Cancer Panel (13 Genes)

Inherited Bone marrow Failure (107 Genes)

This panel is a comprehensive diagnostic tool that consolidates multiple rare but clinically significant genes into a single assay. By covering DNA repair, telomere biology, ribosomal proteins, and hematopoietic regulators, it provides a complete genetic landscape for inherited bone marrow failure syndromes.

Leber Hereditary Optic Neuropathy (LHON)- 3 mutations (G3460A, G11778A, T14484C)

Lynch Syndrome Panel (8 Genes)

MD- Retinoblastoma (RB1 Gene)

Mesothelioma (28 Genes)

Microsatellite Instability Testing (MSI)

Microsatellite Instability (MSI) Testing is a molecular assay used to detect defects in the DNA mismatch repair (MMR) system, a key pathway responsible for correcting errors during DNA replication. Tumours with impaired MMR function accumulate length variations in short repetitive DNA sequences known as microsatellites, resulting in microsatellite instability (MSI). MSI testing is an essential tool in the evaluation of colorectal, endometrial, gastric, and other solid tumours, and plays a critical role in identifying patients who may benefit from immunotherapy and those who may have Lynch syndrome, an inherited cancer predisposition condition.

Multiple endocrine Neoplasia (16 Genes) (includes MEN1/MEN2)

The Multiple Endocrine Neoplasia (MEN) Panel is a comprehensive genetic test designed to detect hereditary conditions that predispose individuals to endocrine tumours. This panel covers 16 clinically relevant genes associated with MEN1, MEN2A, MEN2B, and other hereditary endocrine neoplasia syndromes. These conditions increase the risk of tumours in the parathyroid glands, pituitary gland, pancreas, thyroid, adrenal glands, and other neuroendocrine tissues. Early genetic diagnosis enables personalised surveillance, targeted treatment, and informed family counselling.